Ns Pharma Shares Preliminary Results of Viltolarsen (Ns-065 / Ncnp-01) Phase 3 Clinical Trial (Racer53 Study)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.